CD38 and Miyoshi myopathy: Daratumumab, an anti-CD38 mAb, received FDA approval for treating relapsed or refractory multiple myeloma (R/R MM) in 2016, in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy [54].